SCHEMBL20148061

SCHEMBL20148061

CCN1CCC(C)(C(=O)Nc2ccc(C)cn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.50
MAPT P10636 2/20 0.50
RET P07949 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
LMNA P02545 1/20 0.42
NPC1 O15118 6/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
FPR3 P25089 1/20 0.41
FPR2 P25090 1/20 0.41
WNT3A P56704 1/20 0.41
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069622 0.85 RAB9A (0.54) RAB9AMAPTRETMEN1KMT2A
SCHEMBL20158752 0.82 RAB9A (0.50) RAB9AMAPTRETMEN1KMT2A
SCHEMBL26050285 0.81 NPC1 (0.49) RAB9AMEN1KMT2ASMN1; SMN2LMNA
SCHEMBL21651967 0.74 DRD2 (0.60) RAB9AMAPTMEN1KMT2AKDM4E
SCHEMBL3494822 0.72 RAB9A (0.47) RAB9AMAPTMEN1KMT2AKDM4E
SCHEMBL17450652 0.71 RAB9A (0.57) RAB9AMAPTMEN1KMT2AKDM4E
SCHEMBL24219499 0.70 GSK3B (0.62)
SCHEMBL17450650 0.70 RAB9A (0.56) RAB9AMAPTMEN1KMT2AKDM4E
SCHEMBL19674332 0.70 SMN1; SMN2 (0.46) RAB9AMAPTKMT2ASMN1; SMN2LMNA
SCHEMBL20148034 0.70 POLB (0.49) MAPTRETMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 RAB9A 632/4885MAPT 1499/4885RET 1/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RAB9A 632/4885MAPT 1499/4885RET 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.